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ABSTRACT 
Background: Cervical cancer is treated in various ways depending on the stage of the 
disease. The International Atomic Energy Agency guides the management of cervical cancer 
in resource limited countries. Due to advancement in the existing treatment modalities, a 
higher survivorship rate occurs in women who receive treatment. However, evidence states 
that cervical treatment has pronounced effects on sexual functioning which persists for long 
periods after treatment.  
 
Purpose: The purpose of the study was to explore the sexual function in women after 
completion of treatment at an academic hospital in Johannesburg, South Africa. 
 
Methods: A cross sectional design was used in the study. The sampling method was 
convenience and used a calculated sample size of 147 (n =147). Structured interviews 
collected the data and the Female Sexual Function Index (FSFI) served as data collection 
instrument. Kruskal Wallis tests were used to determine statistical significant difference 
between variables.  
 
Results: The majority of the women (94.6%; n=139) experienced sexual dysfunction which 
persisted over time. The most affected domains in sexual function were arousal and desire, 
while satisfaction was the least affected domain. Pain experienced during sexual activity 
after treatment persisted as time progressed. 
 
Conclusion: The majority of women treated for cervical cancer at an academic hospital in 
the Gauteng Province live with long lasting sexual dysfunction affecting all the domains of 
their sexual function. Although sexual dysfunction reached the highest level in the third 
month after treatment, there was little improvement over time. Age, educational level and 
sexual counselling before treatment did not influence sexual function.  
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CHAPTER 1 
 
ORIENTATION FOR THE STUDY 
 
 BACKGROUND FOR THE STUDY 1.1
According to the International Agency for Research on Cancer and World Health 
Organization (Cancer, 2013), cancer accounted for 8.2 million deaths worldwide with 14.1 
million people newly diagnosed and a population of 32.6 million living with cancer in 2012. 
Cervical cancer is rated as the fourth most common cancer in women in the world and also 
the fourth most common cause of death in women worldwide with the highest being lung 
cancer. In 2012, there were 528,000 women newly diagnosed with cervical cancer and 
266,000 cervical cancer related deaths worldwide. This represents 7.5% of cancer mortality 
in women with a proportion of 87% found in developing countries (GLOBOCAN, 2012). 
Every year in Sub Saharan Africa, there is an estimate of 38.4 newly diagnosed women per 
100,000 whilst 22.5 per 100,000 women would die from this disease (GLOBOCAN, 2012). 
In Africa, with a population of about 267.9 million women above the age of 15 years, it is 
estimated that 80,000 women are diagnosed with cervical cancer each year and more than 
6,000 end up dying reflecting a high mortality rate (Denny and Anorlu, 2012). The age 
standardised incidence rate of cervical cancer per 100,000 in Africa is 28 in middle Africa, 42 
in the Eastern part, 38.2 in South Africa, 29.3 in the West, 12.1 in North Africa, with the 
largest occurrences in East Africa (Denny, 2010). Presently, there is no recent record of 
newly diagnosed women or deaths annually in South Africa due to an improper maintenance 
of the cancer registry (Maree et al., 2013), however, the most current records show cervical 
cancer was responsible for the deaths of 5270 in 2009 and 5433 in 2010 (National Cancer 
Registry, 2010). 
Cervical cancer is treated in various ways depending on the stage of the disease. The 
International Atomic Energy Agency guides the management of cervical cancer in resource 
limited countries (International Atomic Energy Agency, 2012). These guidelines ensure 
effective evidence based health outcomes for women through the selection of appropriate 
treatment regimens depending on the stage of the disease. Curative treatment for invasive 
cancer consists of radiotherapy, brachytherapy, chemo-radiotherapy and surgery. However, 
for stage IIB-IVA cervical cancer, surgery is contra-indicated and external beam radiation, 
brachytherapy, with or without chemotherapy, is recommended. Women with Stage IVB 
cervical cancer can be treated with radiotherapy, with or without chemotherapy. Palliative 
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treatment and care is recommended in women with distant metastasis and the use of 
surgery and radiotherapy are dependent on the patients‟ status and predicated period of 
survival (International Atomic Energy Agency, 2012). 
Unfortunately cancer and its treatment are associated with acute and chronic side effects 
which have a negative influence on women‟s physiological, social, psychological and sexual 
health. For instance, chemotherapy leads to loss of ovarian function, decreased vaginal 
secretion and physiological fatigue. Radiotherapy to the pelvis has effects such as damage 
to the nerves and tissues of the vagina (Abbott-Anderson and Kwekkeboom, 2012), vaginal 
dryness, reduced lubrication, stenosis, atrophy and shortening of the vagina, decreased 
elasticity and fibrosis of vaginal tissues and wall (White et al., 2011).  
 According to Davidson (2011), cervical cancer treatment has pronounced effects on sexual 
functioning, sexual health and sexual activities which persist for a long period even after 
treatment (Reese, 2011) and have a negative influence on the quality of life or the woman 
(Davidson, 2011). Furthermore, alterations in sexual functioning can influence intimacy and 
relationships leading to emotional problems and distress, depression, low self-esteem and 
body image disturbances (Graziottin et al., 2009). Certain psychological responses such as 
fear of pain, altered level of femininity and anxiety also affect sexual responses (White et al., 
2011) which can serve as a  constant reminder of living with cancer (Royo et al., 2014). 
 
 PROBLEM STATEMENT AND SIGNIFICANCE OF THE STUDY 1.2
Little is known about the sexual functioning of South Africa‟s women living with cervical 
cancer, as no African or South African study could be found which explores this important 
issue. Unfortunately patient‟s psychosexual support needs are neglected and not enquired 
about despite the fact that a significant number of cancer patients need the opportunity to 
discuss their sexual concerns (Forster, 2004). This study would therefore raise awareness of 
sexuality in cancer care by providing baseline data regarding the sexual functioning of 
women having to live with cervical cancer and its treatment. In addition, knowledge on 
sexual functioning is essential for nurses to provide evidence based holistic care to these 
women. 
 
 
3 
 
 RESEARCH QUESTION, PURPOSE AND OBJECTIVES OF THE STUDY 1.3
The research question for the study is: What is the sexual functioning in women treated for 
cervical cancer at an academic hospital in Johannesburg, South Africa? The purpose of the 
study is to explore the sexual functioning of women after being treated for cervical cancer at 
an academic hospital in Johannesburg, South Africa. The study aimed at exploring the 
sexual functioning of women treated for cervical cancer in the third, sixth and twelfth months 
after completing the treatment. 
 
       RESEARCH DESIGN AND METHODS 1.4
The study was quantitative and exploratory and used a cross sectional research design and 
conducted at the radiation oncology department of an academic hospital in Johannesburg in 
the Gauteng Province, South Africa. Data were collected from different women during their 
normal scheduled appointments at the radiation oncology clinic three (3) months, six (6) 
months and twelve (12) months after completing treatment.  
The study population consisted of women who were 18 years and older who had completed 
curative treatment for cervical cancer at the radiation oncology department. The sample was 
calculated to be 147 (n=147); with 49 (n=49) in each of the three groups. Convenience 
sampling was used and women were recruited for the study whilst waiting for their follow up 
assessment. Structured interviews were conducted and the Female Sexual Function Index 
(FSFI) served as an interview guide. The data were analysed using the SPSS 22 statistical 
programme and the Kruskal Wallis test determined significance differences between the 
groups.  
 
 DEFINITION OF KEY TERMS 1.5
Sexual health is a state of physical, mental and social well-being in relation to sexuality and 
requires a positive and respectful approach to sexuality and sexual relationships and the 
possibility of having pleasurable and safe sexual experiences free of coercion, discrimination 
and violence (World Health Organization, 2013). 
Cervical cancer is a malignant growth from uncontrolled cell division which invades the 
tissues of the cervix in a woman (National Cancer Institute, 2012). 
Sexual function is an integration of sexual activities, sexual desires, arousal, orgasm, 
lubrication and satisfaction in women (Graziottin et al., 2009). 
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Female sexual dysfunction is a state in which there is a disorder in any of the components 
which make up the phases of the female sexual process (Rosen et al, 2000).  The 
assessment of female sexual dysfunction will be done according to the six domains identified 
by Rosen et al (2000) in the design of a tool used in measuring the sexual function of 
females  
 
 FORMAT OF THE RESEARCH REPORT  1.6
This study will be presented as follows: 
Chapter one: Introduction and background 
Chapter two: Literature review 
Chapter three: Research design and methods 
Chapter four: Results and discussion 
Chapter five: Recommendations, conclusion and summary  
References  
Appendices  
  
5 
 
CHAPTER 2 
 
LITERATURE REVIEW 
Chapter 1 reflected the background, significance as well as the purpose of the study. This 
chapter gives a succinct review of cancer as a health problem and sexual function in cervical 
cancer patients. It explores the concept of cervical cancer, its treatment modalities, related 
side effects and closes with a review on sexual function in women treated for cervical 
cancer. 
 CANCER AS A GLOBAL HEALTH ISSUE 2.1
Cancer is gradually on the increase and is likely to become a disease of high mortality and 
morbidity globally in years to come. Predictions by the United Nations state that the 
population globally by the year 2030 will stem up to 8.3 billion. The steady increase in world 
population will directly reflect an increase in the incidence of cancer to 20.3 million and a 
mortality rate of 13.2 million. This reflects a global increase and burden in comparison to the 
estimate figures of 12.7 million in  2008 and 14.1 million in 2012, while mortality figures were 
7.6 million in 2008 and 8.2 million in 2012 (GLOBOCAN, 2012). Worldwide, there is a steady 
development in societies and economies of countries.  This has a direct influence on the 
increase in the ageing population, increase in growth figures and increasing incidences of all 
forms of cancers and deaths resulting from cancers. Due to population increase and 
economic developments in countries, various risk factors for cancers such as life styles, 
changes in diet patterns and hormonal changes are also contributory factors to the 
increasing burden of cancers (Bray et al., 2012).  
Though certain geographical regions have had high records of incidence rates for specific 
types of cancers, this could be as a result of variations in the distribution of the risk factors 
and a mix of other prevailing factors, such as prevention and early intervention.  Generally, in 
2012, the less developed countries had a population more than half of the global burden of 
cancer (56.8%) and a mortality rate of 64.9% when compared to highly developed countries 
and these figures are projected to increase in years to come (Ferlay et al., 2014). Worldwide, 
as stated by the International agency for Research on Cancer, the most common cancers 
are cancers of the lung, breast, colorectal, stomach, prostate, liver and cervix (GLOBOCAN 
2012). These forms of cancer make up 58% of the entire burden worldwide (Bray et al., 
2012). 
Cervical cancer is the fourth most common cancer in women with the highest cancer 
mortality rate in 55 countries found in Sub Saharan Africa, Asia, Central and South American 
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countries. Also, a record of about 528,000 women was newly diagnosed with cervical cancer 
worldwide with a proportion of 85% found in less developed countries (World Health 
Organization, 2014). In addition, 266,000 women died of cervical cancer in low to middle 
income countries, while only 1 in 10 women died from cervical cancer in high income 
countries. This huge difference can be attributed to  an ineffective cancer control programme 
of prevention, early detection and treatment services in those countries leading to women 
presenting late at an advanced stage, hence the high mortality rate (World Health 
Organization, 2014) 
In Sub Saharan Africa, cancer is on the increase due to the high rate of communicable 
diseases, prevalence of HIV/AIDS, various infections, malaria and other health problems. 
However, cancer has not been given high priority in health. Also, many regions have limited 
resources to aid in early identification of risk factors, appropriate screening services and 
proper preventive measures in cancer control. Population records also reflect an increase in 
population aging and growth, along with a high rise in predisposing factors to various forms 
of cancer. Like other parts of the world, socio-economic development and changes in life 
style further predispose individuals to cancer (World Health Organization, 2014). 
The rate of cervical cancer incidence differs from geographic regions. In South Africa, 
cervical cancer is the second most common cancer in females while being the fourth 
worldwide. It has an Age Standardised incidence Rate (ASR) of 31.5 and remains the most 
common cancer in females of Eastern and Central Africa (World Health Organization, 2014). 
Unfortunately, in the developing regions of the world, most women with cervical cancer 
present at advanced stages, which is then too late to be cured. Cervical cancer affects 
women as young as 15 years of age, but a greater number of women are diagnosed within 
the age groups 30 to 39 or  60 to 69 years (van Schalkwyk et al., 2008). 
Cervical cancer is a preventable disease by performing cervical cytology and referring 
women with abnormal cytology for specific follow up and treatment of precancerous lesions. 
In 2001, the National Department of Health in South Africa commenced  a national 
programme for cervical cancer screening which allows three free Pap smears at health 
clinics for asymptomatic women aged 30 and above at a ten year interval (Maree et al., 
2013). The aim of the programme was to reduce the incidence of cervical cancer to half by 
75% coverage (van Schalkwyk et al., 2008). The uptake of these screening services has 
faced various challenges, such as lack of knowledge and awareness of cervical cancer, 
access and transport difficulties to screening centres, lack of motivation and anxiety about 
the procedures of the tests (Maree and Wright, 2011), resulting in screening uptake as low 
as 13% (Snyman, 2012). 
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Cervical cancer is caused primarily by the persistent infection of specific oncogenic forms of 
the Human Papilloma Virus (HPV). Transmission routes include sexual intercourse, contact 
through skin to skin and contact with body fluids during sexual activity. Predisposing factors 
are multiple sexual partners, sexually transmitted infections and early initiation of sexual 
activities (Maree and Wright, 2011). HPV infections are asymptomatic in nature and could 
resolve on their own, however if such persists, it develops to precancerous forms which 
could later develop into cancer within 10 to 20 years. Currently there are available vaccines 
for prophylaxis which can be given to girls aged 9 to 13 years (or the age range stipulated by 
the guidelines of the country), or before they initiate sexual activity; before exposure to the 
type of HPV in the vaccine (Denny and Anorlu, 2012). 
 
 TREATMENT OF CERVICAL CANCER IN LIMITED RESOURCE SETTINGS 2.2
Various guidelines exist for treating women with cervical cancer. However, the International 
Atomic Energy Agency (IAEA) has drawn up specific guidelines for the management of 
cervical cancer in limited resource centres which serve as a guide to radiation oncologists 
(International Atomic Energy Agency, 2012). These set guidelines are standardised, easy to 
understand and evidenced based and can be adapted to suit the specifics of each centre or 
region. For the purpose of curative treatment, patients are classified into two groups based 
on the FIGO staging system:  
 Early stage : IA-IB1-IIA1-IB2 and IIA2 <= 4cm 
 Advanced stage : IB2 and IIA2>=4cm-IIB-IIIB-IVA 
The treatment of women with early stage cervical cancer includes surgery and radiotherapy, 
similar to those with advanced cervical cancer Stage IB2 and IIA2. Women with Stages IIB 
to IVA cervical cancer are not suitable for surgery and are treated with external beam 
radiation and brachytherapy, with or without concomitant chemotherapy; most commonly 
cisplatin given weekly for five cycles during external beam radiation. Curative treatment with 
radiotherapy, with or without chemotherapy, could be considered for women with Stage IVB 
cancer with para-aortic node involvement, whilst those with distant metastasis are treated 
with palliative intent (International Atomic Energy Agency, 2012).  
The total period of treatment is a strong determinant in the outcomes of radiotherapy 
treatment, improvement of local control and survival and should be taken into consideration 
in the planning of treatment. The overall radiotherapy treatment time entails the period from 
the first to the last dose of radiotherapy and should not extend beyond eight weeks, 
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therefore, delays and interruptions in between should be prevented  (International Atomic 
Energy Agency, 2012). 
 
 TREATMENT RELATED SIDE EFFECTS 2.3
Technology and advancement in the treatment of cervical cancer has led to the cure and 
survivorship of over 70% of women who are treated (Greimel et al., 2009).The quality of life 
of women after treatment for gynaecological cancer is vital. Unfortunately, sexual functioning 
has been greatly affected and has a negative influence on the quality of life in as many as 40 
to 100% of women (Audette and Waterman, 2010). Also, the total experience of a diagnosis 
of cancer,  as well as the course of treatment, has a detrimental effect on the self-image and 
psycho-sexual state or sense of sexuality of a woman (Falk and Dizon, 2013). 
Women receiving chemotherapy and radiotherapy to the pelvis experience various side 
effects which include vaginal changes, fatigue, alopecia and skin changes and emotional 
problems which could influence their sexual behaviour and fulfilment.   
Vaginal changes consist of vaginal dryness and atrophy due to depletion in the level of 
oestrogen production caused by ovarian failure. Ovarian failure can lead to dyspareunia and 
a decline in the level of sexual interest, arousal, desire, hot flushes and sleep disorders. 
Women also experience an increase in anxiety and a high level of fear of pain and actual 
experience of pain (Oskay et al., 2011). In addition, vaginal stenosis, coital bleeding, risk of 
fistula, shortened length of vagina and reduced flexibility also occur (Audette and Waterman, 
2010). Radiotherapy causes shortening in length of the vagina and fibrosis, which has a 
negative impact on the sensitivity of the clitoris and genital areas during sexual activity and 
decreases the extent of vaginal penetration  (Oskay et al., 2011). Fibrosis occurs due to 
inflammation and damage to the connective tissues and the mucosa of the vagina, which 
has a negative influence in attainment of orgasm and lubrication. This can be a late effect 
and can be reported as late as five years after treatment (Falk and Dizon, 2013).  
Generalised fatigue, a common complication of cancer and its treatment, has a negative 
influence on sexual drive and desire and leads to loss of sexual energy and a reduction in 
desire to maintain sexuality  (Oskay et al., 2011). Pubic alopecia can affect the female self-
esteem, perception and sexual attractiveness (Falk and Dizon, 2013) and reduce a woman‟s 
desire to maintain her level of sexuality and attraction (Oskay et al., 2011). Additionally, 
emotional changes consisting of depression, anxiety, isolation, withdrawal, disturbed self-
perception and image, stress, role shifting and avoidance of sexual intimacy with partner 
(Reese, 2011) have an impact on the sexual function as it is made up of an interconnection 
of psychological, emotional, cultural elements and physiologic factors (Audette and 
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Waterman, 2010). Also, Reese (2011) reported that studies indicate that survivors of 
gynaecological cancer reported less intimacy with partners in forms of kissing, caressing, 
sexual fantasy and that emotional distress over sexual concerns were common in cancer 
survivors. 
 
 SEXUAL FUNCTION 2.4
2.4.1 Sexuality  
In oncology care, attention to sexual issues are inadequate with minimal regard given as it is 
highly  underreported (Serati et al., 2009). Sexuality is a core aspect of humans and it entails 
sex, gender identity, sexual orientation, intimacy, reproduction and personality concept. 
Sexuality is a reflection of an individual‟s personality and lifestyle (Graziottin et al., 2009) and 
can be experienced and expressed in thoughts, fantasies, desires, beliefs, attitudes, values, 
behaviours, practices, roles and relationships. Sexuality is influenced by the interaction of 
biological, psychological, psychosexual, social, economic, political, cultural, ethical, religious 
and spiritual factors (Graziottin et al., 2009). In women, sexuality includes personal feelings 
about their bodies, femininity, fertility and sexual functioning which involves ability to partake 
in sexual activities and satisfaction of their partners (Graziottin et al., 2009). Sexual 
behaviour is an evident manifestation of sexuality.  Also, female sexual response consists of 
excitement, plateau, orgasm and resolution which is interconnected in a coordinated 
sequence of different phases (Rosen et al, 2000) Any abnormality in the physiology and 
psychological cyclic  response can lead to sexual dysfunction (Royo et al., 2014). 
2.4.2 Sexual health 
According to the World Health Organization, “Sexual health is a state of physical, emotional, 
mental and social well-being in relation to sexuality; it is not merely the absence of disease, 
dysfunction or infirmity. Sexual health requires a positive and respectful approach to 
sexuality and sexual relationships, as well as the possibility of having pleasurable and safe 
sexual experiences, free of coercion, discrimination and violence. For sexual health to be 
attained and maintained, the sexual rights of all persons must be respected, protected and 
fulfilled” (World Health Organization, 2006, pp.5). 
Graziottin et al. (2009) identified three major interrelated dimensions of sexual health in 
women: female sexual identity, sexual function and sexual relationship interact to give 
women‟s sexual health its full meaning or its problematic profile. Sexual function is vital to 
women and it is important to support cancer survivors in relation to their sexuality during and 
after their treatment (Olsson et al., 2012). Cervical cancer usually affects younger women at 
a mean age of about 50 years in comparison to other forms of gynaecological cancer; these 
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women have a longer life expectancy after treatment. Hence, the focus shifts to ensuring a 
high quality of life in survivors (Ye et al., 2014) as supported by Plotti et al. (2011), who 
stated that the development in treatment of cervical cancer has made the five year survival 
rates of women with early stage cancer higher. When they are cured, their life expectancy 
can be as long as 25 to 30 years post treatment and they are faced with the challenges of 
coping with the impairment from the cancer and its treatment for long periods during their life 
time.  
2.4.3 Classification and domains of sexual function 
According to the American Psychiatric Association (2000), sexual dysfunction involves the 
alteration in the psycho-physiological process of the cycle of sexual response and its other 
characteristics. The cycle of sexual response involves the following phases:  
 Desire: the inclination driven towards sexual activity. 
 Excitement: physiological impulses which drive a sense of sexual pleasure. 
 Orgasm: contractions of the perineal muscles and walls of the vagina and a burst of 
sexual excitement with ejaculation of semen in males. 
 Resolution: muscular relaxation and sense of wellbeing. 
Female sexual dysfunction is characterised by a group of sexual disorders which have a 
significant adverse effect on the quality of life and interpersonal relationships thereby 
causing distress. Based on the framework of the DSM-V: Diagnosis and statistical Manual of 
Mental Disorders of the American Psychiatric Association, there are three forms of sexual 
disorders involved in female sexual dysfunction.  This is opposed to the old framework of the 
DSM-IV which classified them into more categories. (IsHak and Tobia, 2013)  
These new framework categorises female sexual dysfunction into: 
 Female sexual interest/ arousal disorder (formerly female hypoactive desire 
dysfunction and female arousal dysfunction) 
 Female orgasmic disorder 
 Genitopelvic pain/penetration disorder (formerly dyspareunia and vaginismus)  
(IsHak and Tobia, 2013). 
 
The Female Sexual Function Index (FSFI), an instrument validated for use in the 
assessment of female sexual function which is widely in use, was standardised on the 
previous framework as described by the DSM-IV and ICD-10 International classification of 
diseases.  (Rosen et al, 2000). Each of the different disorders in this former framework: 
hypoactive sexual desire disorder, sexual arousal disorders, sexual pain disorders and 
orgasmic disorders corresponds to the domains of sexual function in the FSFI (Rosen et al 
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2000). According to Rosen (2000), sexual satisfaction is a vital aspect of sexual function, 
although it was not classified in a separate category in the classification system. For the 
assessment of sexual function in this study, six domains apply: 
 sexual arousal,  
 sexual desire,  
 lubrication,  
 orgasm,  
 pain and  
 satisfaction.  
The above domains are as stated in the female sexual function index (FSFI), an instrument 
designed for the assessment of female sexual function in women (Rosen et al, 2000).   
In conclusion, sexual response is an interconnection of a coordinated set of events and an 
alteration in one domain has an influence with other disorders, resulting in an overlap in 
categories of classification for diagnosis (Rosen et al, 2000). 
 
 SEXUAL FUNCTION IN WOMEN WITH CERVICAL CANCER  2.5
A number of problems are associated with gynaecological cancers including the 
development of negative perceptions of sexual self-concept and sexual function (Bae and 
Park, 2015). According to Bober et al. (2013),  patients undergoing treatment and cancer 
survivors experience similar problems related to the detrimental effects on sexual desire, 
arousal, orgasm and sexual pain. In addition, long term sexual dysfunction has been 
observed in more than 50% of patients undergoing treatment for breast, colorectal and 
gynaecological cancers (Bober et al., 2013).  For cervical cancer patients, some problems 
persist for long periods after treatment. Corrêa et al. (2015), report that approximately 70% 
of cervical cancer survivors experience sexual dysfunction including alteration of sexual 
desire, vaginal dryness, soreness, bleeding, dyspareunia and vaginal atrophy after 
treatment. However, Sadovsky et al. (2010), when reviewing the literature found 30% to 63% 
of women experience sexual problems when treated for cervical cancer. In addition, Tang et 
al. (2010) found that whilst the frequency of sexual activity was not reduced, sexual drive 
and overall satisfaction was reduced, with reduction in the frequency of kissing and 
caressing. 
Sexual function differs throughout the lifetime of a woman, varying from age group and stage 
of disease as well as treatment received (Oskay et al., 2011).  Multiple complications could 
arise as a result of treatment strategies leading to sexual dysfunction caused by a complex 
interaction between the direct side effects from the treatment and the indirect effects of 
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emotional handling from the part of the women regarding withdrawal, isolation and 
anticipation of treatment outcome; anxiety could further aggravate sexual problems (Plotti et 
al., 2011). According to Greimel et al. (2009), radiotherapy appears to lower sexual activity 
rate in women, whilst Vaz et al. (2011) report radiotherapy causes a decreased level of 
sexual interest. In addition, Rodrigues et al. (2012) reports reduced levels of orgasm and 
altered sexual arousal owing to impaired blood flow innervations and premature menopause 
which is caused by radiotherapy. 
Not only women‟s sexual function is affected by cervical cancer and its treatment, as Reese 
(2011) suggests that cancer treatments affect the sexual function of partners as well as the 
cancer survivors. Sterba et al. (2011), in a study of sixty eight (68) gynaecological cancer 
patients and their partners, found 74% of the patients‟ partners acknowledged vagina 
dryness after cancer treatment, whilst 41% of patients reported the reduction in sexual 
function. According to Stafford and Judd (2010), the spouse plays a significant role in judging 
and evaluating the aspects vital to the sexual relationship of the couple. Nanton et al. (2010) 
observed that sexual dysfunction of men with prostate cancer was minimised by their 
spouses, thus implying the alleviation of the detrimental effect of cancer on sexual function 
can be lessened by the spouse. Tang et al. (2010) reports that prior sexual dysfunction 
before cancer treatment may engender greater difficulty in effectively handling cancer 
related sexual difficulties.  
Cancer treatment does not only have detrimental effects on sexual relationships, as some 
couples report an increased sexual intimacy despite the harmful effects of cancer treatments 
(Flynn et al., 2011). Lindau et al. (2011) reports increased noncoital physical closeness, 
solidarity in relationship and emotional support and appreciation following treatment. In 
addition, some particular strategies, such as effective communication, help couples improve 
their ability to cope with the illness and experience better quality of intimacy (Badr et al., 
2010) which depends on the significance of the relationship role in coping with cancer 
treatment (Reese, 2011).   
 
 SUMMARY  2.6
In this chapter, the literature relating to cancer and cervical cancer, cervical cancer 
treatment, the side effects of cervical cancer and how it influences sexual function was 
described. The next chapter presents the research design and methods used in the study. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODS 
 
Chapter 2 described the literature pertaining to the concept of sexual function in relation to 
treatment of cervical cancer. This chapter gives an overview of the research design and 
methods of the study as well as the ethical considerations applied in the study. 
 
 RESEARCH DESIGN 3.1
According to Burns and Grove (2012), the research design is a step-wise plan which gives 
direction to a study based on its set objectives. The research design ensures that pre-
identified and adequate control measures are put in place as preventive procedures against 
factors that can influence the research findings. It also guides the appropriate strategy for 
implementation of the study in the choice of the research population, method of gathering 
data and how generated data will be analysed (Burns and Grove, 2012). The study used a 
cross sectional design.  A cross sectional design aims to investigate various sets of 
respondents at different levels or grades thereby giving an explanation into the variations 
based on specific aspects under study in the groups. Cross sectional studies obtain 
information at the same time within the same given population once (Burns and Grove, 
2012).  
 RESEARCH SETTING  3.2
The research setting is the particular site where the study will be carried out and data 
collected (Burns and Grove, 2012). The study was conducted in the radiation oncology 
department of an academic hospital in Johannesburg.   
The hospital has approximately 4000 staff members and 1088 beds serving individuals from 
the Gauteng Province, other provinces and from neighbouring countries. Services offered 
range from secondary, tertiary, referral and specialised care on an inpatient as well as 
outpatient basis. The cost for these services is carried by a National Tertiary Service Grant 
and funds allocated to the province. In addition, the hospital serves as the main teaching 
hospital for the Faculty of Health Sciences at the University of the Witwatersrand, providing a 
platform for learning and services for undergraduate and postgraduate students. The 
hospital has a large oncology section with both medical and radiation departments. This 
section runs various clinics serving a large number of patients and wards for admission. The 
radiation unit is well equipped with state of the art machinery and equipment also serving a 
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huge number of patients. The staffs are well trained, skilled and competent in the care of 
oncology patients and have a high record in the treatment of all forms of cancers, including 
cervical cancer. They offer care to a large number of women with cervical cancer every year 
(University of the Witwatersrand, 2015) most commonly on an out-patient basis. Women 
treated for cervical cancer return to the department regularly as they are assessed three 
monthly for two years, six monthly for another two years and thereafter once a year after the 
completion of their treatment. 
 
 POPULATION AND SAMPLING 3.3
The research population is the overall group of individuals who conform and meet up to 
specific stipulated yardsticks laid out as inclusions in the study. The population includes the 
set of people to whom universality of the study will be applicable (Burns and Grove, 2012). 
The study population was all women of 18 years and older, who had completed curative 
treatment for cervical cancer, thus being diagnosed with Stage IIB- IVA cervical cancer. The 
target population was all women who received the aforementioned treatment and came for a 
follow up assessment three, sixth and twelfth months after treatment. These three study 
groups were selected as women are scheduled in this radiation clinic for follow up care in 
their third, sixth and twelfth months after their treatment is completed.  
Convenience sampling selected the sample. Convenience sampling is a technique of 
selecting individuals who are readily available and found at the right place and right time. 
Only available individuals are recruited till the desired number is reached (Burns and Grove, 
2012). This sampling method was appropriate for the study as it allowed the researcher to 
include women returning to the clinic for a scheduled follow up assessment.  
Based on statistical consultation, the sample size was calculated at a desired level of 
significance with confidence interval 95%, a z value of 1.96 and a marginal error (D) of 0.5 
standard deviation (S) of outcome variables (from a previous validation study) of 3.08   
(Meston, 2003) using the formula below:  
Sample size   N=
(Z /2S)
2
D
 
The derived sample size gives 147 respondents with a number of 49 in each group in the 
third, sixth and twelfth months of follow up care.  
Women who were waiting for their follow up assessment in the radiation oncology 
department were recruited and this recruitment continued until the sample size was reached 
(Burns and Grove, 2012). 
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 DATA COLLECTION AND INSTRUMENT  3.4
Data are information which is gathered systematically in a study. Data collection is the 
process whereby data are collated in an organised method that gives a definition to the 
specific variables being studied and applicable to the set objectives and purpose of the study 
(Basavanthappa, 2010).  Data were collected by means of structured interviews using the 
Female Sexual Function Index (FSFI) (Appendix D) as the data gathering instrument. A 
structured interview is an orderly, systematic process of data collection using a list of 
questions which have been prepared prior to the interview as a guide. Using and interview 
guide helps to ensure consistency by asking the respondents the same set of standard 
questions in the same order (Burns and Grove, 2012). Using structured interviews allowed 
the researcher to ensure that questions and concepts were clearly understood as 
respondents could ask questions for clarification thus enhancing coherence (Burns and 
Grove, 2012). It also allowed the researcher to not exclude respondents based on their 
literacy level. 
 The Female Sexual Function Index (FSFI) served as the interview guide, a tool used for the 
collection and documentation of information generated from a list of clearly stated questions 
and instructions in line with the objectives of the study (Burns and Grove, 2012). The 
interview was conducted in a comfortable private room and women who met the inclusion 
criteria, waiting for follow up care, were approached. A 100% response rate was achieved as 
all the women who were approached agreed to participate in the study voluntarily. The data 
were collected from 13th July to 25th August 2015.  
The FSFI is a validated self-administered instrument used to assess female sexual function. 
However, in this study, it was used as a researcher administered questionnaire because 
being in the English language, respondents might not have been able to read and speak 
more than Basic English. The Registered Nurses practicing in the radiation oncology unit 
volunteered to assist the researcher with language issues should it arise however, such 
assistance was not needed.  The FSFI is in the open domain for use and permission is not 
required for its use in this study. 
The FSFI was developed by Rosen et al. (2000) in a study conducted on assessment of 
female sexual functioning and is one of the most widely used measures of female sexual 
function. The validation study reported excellent internal consistency reliability coefficients 
for the total FSFI score and subscales with Cronbach alpha value range of 0.82 to 0.96 
(Rosen et al, 2000)   
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 In a study by Baser et al. (2012) to evaluate the reliability and construct validity of the 
instrument in assessing sexual function in female cancer survivors. The Cronbach alpha 
value for the FSFI total score was 0.94 while in the subscales it ranged from 0.85 (for 
Satisfaction) 0.94 for Lubrication)  
 
 The instrument consists of nineteen (19) items which assesses sexual activity during the 
previous four (4) weeks. It measures sexual function in six (6) domains; sexual desire (two 
items), arousal (four items), lubrication (four items), orgasm (three items), satisfaction (three 
items) and pain (three items). Each domain has a score on a scale of 0 to 6 represented on 
an ordinal Likert-type response format, with a score of 0 representing no sexual activity and 
a score of 6 indicating the highest level of functioning  (Baser et al. 2012) 
 
The score from each domain is derived by the addition of the score of each item in the 
domain and multiplying by its corresponding factor. The total sexual function score is 
obtained by adding up the scores of all domains. The total score ranges from 2 and 36, with 
a higher score indicating better sexual function (Rosen et al, 2000).  
 
According to Royo et al. (2014), the cut off points for each domain of 3.6 and below 
represents dysfunction, while the FSFI full score of 26.55 and below represents dysfunction 
in the total sexual function (Wiegel et al., 2005). The data collection was planned as follows: 
 The researcher was present in the clinic with copies of the data collection instrument, 
consent forms and information sheets on the scheduled days of the week dedicated 
to follow up appointments in the gynaecology clinic. 
 The researcher approached women while they awaited their turn for follow-up. It was 
ensured they did not lose their turn in the queue whilst the structured interviews were 
being conducted. 
 Written informed consent was obtained and the contents of the information sheet 
were duly explained to the women. 
 Arrangements were made with the head of the unit as well as the Registered Nurses 
within the clinic for counselling. A total number of eight women were referred for 
counselling support during data collection.  
 The data collection period lasted for six weeks and ended when the entire sample 
size was reached. 
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 DATA ANALYSIS 3.5
Data analysis is the structuring, computation and interpretation of data. In relation to data 
analysis is the structuring, computation and interpretation of data relating to the research 
problem identified (Burns and Grove, 2012). Data collected were captured and computed on 
a statistical spreadsheet in various categories and analysed using the statistical programme 
SPSS 22 utilising descriptive statistics of mean, mode and standard deviation to analyse the 
variables. The Kruskal Wallis test, a nonparametric test used to determine the statistical 
significance between two or more groups, was used to determine if there is a significance 
difference between the variables. This test is used when each condition being assessed is 
carried out by a different group of participants and was appropriate for the study as the data 
involved are not normally distributed (Hole, 2011). 
 ETHICAL CONSIDERATIONS 3.6
Ethical considerations involve the actions put in place to ensure research is carried out 
without posing any threat or harm to the respondents involved. According to Burns and 
Grove (2012), ethical consideration entails ensuring appropriate informed consent is 
obtained from participants, presenting a research proposal submitted for institutional review 
and preserving the rights and shielding participants from harm during their involvement in a 
research study.  Hence, the study must be carried out systematically and competently to 
uphold human rights, respect and dignity. Appropriate reference must be given to various 
contributors involved in the study with outcomes of the study being disseminated 
appropriately. Principles of confidentiality, informed consent, proper data handling, right to 
withdraw from study, adequate information on study and potential risks or benefit must be 
ensured during the research process (Brink et al. 2012). 
During the research process, the following steps were taken: 
 The research proposal for this study was peer reviewed by the faculty of the 
Department of Nursing Education and Assessor‟s Group of the School of Therapeutic 
Sciences. In addition, official approval was obtained from the Postgraduate Research 
Committee of the Faculty of Health Sciences. 
 Ethical clearance was obtained from the Human Research Ethical Committee of the 
University of the Witwatersrand; ethical clearance number M150432 (Appendix F). 
 Permission to conduct the study was obtained from the Director of Nursing and Chief 
Executive Officer of the hospital. The Unit Manager (Nursing) and clinical head of the 
radiation oncology department also approved and supported the study. 
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  Informed written, voluntary, consent was obtained from each of the participants. 
Information was given on the purpose, objectives of the study and the respondent‟s 
right of withdrawal, anonymity and confidentiality were stated.  
 Due to the sensitivity of the questions, the data were collected in a private room with 
only the respondent and researcher present. In addition, arrangements were made 
with the nurse in charge of counselling in the radiation oncology department to 
counsel respondents should they become emotionally distressed. 
 The researcher ensured the maintenance of anonymity, confidentiality of information 
and the privacy of respondents. Structured interviews were carried out in a private 
room, away from the waiting area, using the data collection instrument as a guide. 
Respondents were approached individually, after detailed explanation on the concept 
of the study, informed consent was obtained. Also each question on the 
questionnaire was asked by the researcher and properly explained to respondents. 
The researcher ticked the selected option on the questionnaire used as a guide. 
Completed questionnaires were placed in large brown envelopes without the names 
of respondents on them and therefore could not be traced to each respondent. Good 
communication skills were used during the interview sessions and participants were 
assured of counselling support should any emotional discomfort arise.   
 Confidentiality and anonymity was maintained throughout the study and data 
gathered in the study was analysed appropriately. The data gathering tool was coded 
and numbered sequentially with numbers without the respondents‟ names and 
collated in an envelope thereby making it impossible to link the respondents to the 
numbered completed questionnaires.  
 Data were collected until the sample was realised. The data collected were only 
accessible to the researcher and supervisor. 
 
 SUMMARY  3.7
This chapter described the research design, methods, data collection instrument, process, 
analysis and ethical consideration in the study. The discussion of findings from the study will 
be presented in the next chapter. 
  
19 
 
CHAPTER 4 
RESULTS AND DISCUSSION 
 
Chapter 3 presented the research design and methods used in this study. This chapter 
focuses on the findings and discussion. In this study, data were collected from a total of 147 
women by means of structured interviews using the Female Sexual Function Index (FSFI) as 
the data gathering instrument. The sexual function of these women was explored in three 
groups: Group 1 (n=49) represents women three months after completing treatment, Group 
2 shows (n=49) those six months after treatment and Group 3 represents women (n=49) 
twelve months after treatment. Inferences were drawn based on statistical analysis and 
evidence from gathered data and reported based on the six domains of sexual function and 
the total score of the FSFI. 
 
 DEMOGRAPHIC PROFILE OF THE RESPONDENTS 4.1
The ages of the sample (n=147) ranged from 30 to 73, with the largest proportion (42.9%; 
n=63) being between the ages 40 to 49. The mean age was 45.7 ± 9.2 years and median 
age was 44.  The majority of the sample (52.4%; n=77) had a high school education, whilst 
39% (n=58) were functionally illiterate. Only 12 women (8.2%) had tertiary education. More 
than half of the sample (61.9%; n=91) indicated they had received sexual counselling before 
treatment. The greatest percentage of the sample (49.7%; n=73) were employed, whilst 
44.2% (n=65) were unemployed and the remaining 6.1% (n=9) were retired. Most were 
single (62.5%; n=92). The majority (60.5%; n=89) were treated with external beam radiation 
(EBR) and brachytherapy only, while 39.5% (n=58) received a combination of EBR, 
brachytherapy and chemotherapy. The general information of the three groups is presented 
in Table 4.1. 
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Table 4.1 Demographic profile of the respondents (n=147) 
Variable Group 1 Group 2 Group 3 Total 
Age n % n % n % n % 
   30-39 17 34.7 10 20.4 15 30.6 42 28.6 
   40-49 23 46.9 18 35.7 22 44.9 63 42.9 
   50-59 6 12.2 14 28.6 10 20.4 30 20.4 
   60-69 2 4.1 5 10.2 2 4.1 9 6.1 
   70-79 1 2.0 2 4.1 0 0 3 2.0 
Educational level         
   Primary school  16 32.7 26 53.1 16 32.7 58 39.5 
   Grades 8-10 6 12.2 7 14.3 8 16.3 21 14.3 
   Grade 11-12 22 44.9 12 24.5 22 44.9 56 38.1 
   Tertiary education 5 10.2 4 8.2 3 6.1 12 8.2 
Employment status         
   Unemployed 21 42.9 24 49 20 40.8 65 44.2 
   Employed  27 55.1 19 38.8 27 55.1 73 49.7 
   Retired  1 2 6 12.2 2 4.1 9 6.1 
Marital status         
   Single  30 61.2 26 53.1 36 73.5 92 62.6 
   Married  18 36.7 20 40.8 12 24.5 50 34.0 
   Divorced  1 2.0 3 6.1 1 2.0 5 3.4 
Sexual counselling received 
before treatment 
        
   Yes  34 69.4 25 51 32 65.3 91 61.9 
   No  15 30.6 24 49 17 34.7 56 38.1 
Type of treatment received          
   External beam radiation and      
brachytherapy 
32 65.3 28 57.1 29 59.2 89 60.5 
   External beam radiation,   
brachytherapy and 
chemotherapy 
17 34.7 21 42.9 20 40.8 58 39.5 
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 THE DOMAINS OF SEXUAL FUNCTION  4.3
The majority of the sample (80.3%; n= 118) reported being sexually active in the preceding 
four weeks prior to data collection. There was an increase in sexual activity as time 
progressed from three months (79.6%; n=39) to six months (83.7%; n= 41), while there was 
a decline in those involved in sexual activity in the group of twelve months (77.6%; n=38) 
(Figure 4.1). A Kruskal Wallis test found no statistically significant difference in the 
involvement in sexual activity as time progressed in the three groups.  
 
 
Figure 4.1.Sexual activity according to the three groups  
 
When exploring the six domains of sexual function in the total sample: desire, arousal, 
lubrication, orgasm, satisfaction and pain, it was found that satisfaction had the highest 
mean score of 3.1 (SD ± 1.5), whilst arousal had the lowest mean score of 2.2 (SD ± 1.4). 
When applying the 3.6 cut off point (Royo et al., 2014) all the domains indicated dysfunction.  
The mean score of the full FSFI score of the entire sample (n=147)  was 15.1 (SD ± 7.4) 
indicating a dysfunction in the whole sample when applying the cut off score of 26.55 for the 
full score as described by Wiegel et al. (2005). The details of the domains and their means 
scores are presented in Table 4.2 and Figure 4.2. 
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Table 4.2 Average scores for sexual function (n=147) 
Domain  Mean ± SD 
Desire  2.5 ± 1.0* 
Arousal  2.2 ± 1.4* 
Lubrication  2.4 ± 1.5* 
Orgasm  2.5 ± 1.5* 
Satisfaction  3.1 ± 1.5* 
Pain  2.4 ± 1.7* 
FSFI full scale score  15.1 ± 7.4* 
*indicates sexual dysfunction 
 
 
 
Fig. 4.2. Average scores for domains of sexual function  
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 DOMAINS OF SEXUAL FUNCTION ACCORDING TO THE THREE GROUPS 4.4
When comparing the domains of the groups, Group 2 had the highest mean scores in the 
desire and arousal domain, 2.6 ± 1.0 and 2.3 ± 1.3 respectively. In the lubrication and 
orgasm domains, both Groups 2 and 3 had same mean scores of 2.4 (SD±1.5) and 2.4 (SD± 
1.6) respectively, which were higher than that of Group 1. Group 2 had the highest score of 
3.4 ± 1.5 in the domain of satisfaction, whilst Group 3 scored the highest mean in the pain 
domain; 2.8 ± 3.0 (Figure 4.3).  
On the full FSFI score, Groups 2 and 3 had same mean scores of 15.7 ± 7.1 and 15.7 ± 8.0 
respectively. Although these scores were the highest scores within the groups, they are all 
below the set cut off point of reference, hence indicating sexual dysfunction in each of the 
domains within all three groups. Across the three groups, Group 1 had the lowest scores in 
all the domains as well as in the full FSFI score.  
When analysing the relationships between the variables, the Kruskal Wallis test was used 
with a p-value representing statistical significant difference at values ≤0.05. Statistical 
significant differences existed between pain and the time after completion of treatment 
(three, six and twelve months) χ2 (2) = 6.85, p=0.033, also between satisfaction and the type 
of treatment received: Kruskal Wallis χ2 (2) = 4.02, p=0.045. There was no significant 
difference between age, educational level and employment status. The mean scores in each 
domain in the three groups are presented in Table 4.3. 
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Table 4.3   Sexual function according to the domains in each group (n=49) 
Domains   Mean scores ± SD P value  
Group 1 Group 2 Group 3 Time after 
completing 
treatment 
Treatment 
received    
Desire  2.4 ± 1.0 2.6 ± 1.0 2.5 ± 1.0 0.45 0.26 
Arousal  2.1 ± 1.4 2.3 ± 1.3 2.2 ± 1.4 0.48 0.62 
Lubrication  2.2 ±  1.5 2.4 ± 1.5 2.4 ± 1.6 0.61 0.45 
Orgasm  2.3 ± 1.6 2.5 ± 1.4 2.5 ± 1.7 0.56 0.43 
Satisfaction  2.9 ± 1.6 3.4 ± 1.5 3.2 ± 1.4 0.22 0.045* 
Pain  2.0 ± 1.5 2.5 ± 1.5 2.8 ± 2.0 0.033* 0.81 
Full FSFI score  13.9 ± 7.1 15.7 ± 7.1 15.7 ± 8.0 0.10 0.31 
*significant difference; p≤0.05 
 
 
 
 
Fig 4.3 Sexual function according to the domains in each group 
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 COMPARISON BETWEEN SEXUAL DYSFUNCTION AND GOOD SEXUAL FUNCTION  4.5
When exploring the six domains of sexual function, desire, arousal, lubrication, orgasm, 
satisfaction and pain, as well as the full FSFI score in the total sample, all the domains had a 
higher percentage of women with sexual dysfunction compared to those with a good level of 
sexual function. When applying the set cut off point (Royo et al., 2014) across the total 
sample (n=147), the domain desire reported the highest percentage women with dysfunction 
(93.9%; n=138), followed by arousal (91.8%; n=135), lubrication (87.1%; n=128), orgasm  
(85.0%; n=125) and pain (81.0%; n=119). The domain satisfaction had the lowest 
percentage of dysfunction (67.3%; n=99) (Figure 4.4 and 4.5). As reflected by the full FSFI 
score, almost all the women had sexual dysfunction (94.6%; n=139).  
The proportion of women in the categories of sexual dysfunction and good sexual function is 
described according to each group in Table 4.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
 
Fig 4.4 Sexual dysfunction in the domains according to the three groups 
 
 
 
Fig 4.5 Good sexual function in the domains according to the three groups 
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Table 4.4 Comparison between sexual dysfunction and good sexual function (n=49)  
 Sexual Function Group 1 Group 2 Group 3 Total  
Domains   Category n % n % n % n % 
Desire 
Sexual 
dysfunction* 
47 95.9 44 89.8 47 95.9 138 93.9 
Good sexual 
function**  
2 4.1 5 10.2 2 4.1 9 6.1 
Arousal 
Sexual 
dysfunction  
45 91.8 45 91.8 45 91.8 135 91.8 
Good sexual 
function  
4 8.2 4 8.2 4 8.2 12 8.2 
Lubrication 
Sexual 
dysfunction  
45 91.8 40 81.6 43 87.8 128 87.1 
Good sexual 
function  
4 8.2 9 18.4 6 12.2 19 12.9 
Orgasm 
Sexual 
dysfunction  
43 87.8 42 85.7 40 81.6 125 85.0 
Good sexual 
function  
6 12.2 7 14.3 9 18.4 22 15.0 
Satisfaction 
Sexual 
dysfunction  
34 69.4 30 61.2 35 71.4 99 67.3 
Good sexual 
function  
15 30.6 19 38.8 14 28.6 48 32.7 
Pain 
Sexual 
dysfunction  
46 93.9 42 85.7 31 63.3 119 81.0 
Good sexual 
function  
3 6.1 7 14.3 18 36.7 28 19.0 
Full FSFI 
score 
Sexual 
dysfunction  
46 93.9 47 95.9 46 93.9 139 94.6 
Good sexual 
function  
3 6.1 2 4.1 3 6.1 8 5.4 
 
Scores *0-3.6 indicates sexual dysfunction while **3.7-6.0 indicates good sexual function 
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There was a wide margin between women with scores below the set cut off and those with 
scores above in all three groups in each domain. The same trend was found in the FSFSI full 
scores of all groups when applying the cut off score. (Figure 4.6)  
 
 
 
 
Figure 4.6 Full FSFI scores according to the three groups 
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Statistically significant difference was determined between the time after treatment and the 
domains pain, satisfaction and type of treatment received. No statistical significant 
differences were found between age, sexual counselling received, educational level and 
employment status. Although no statistically significant difference existed between sexual 
function and age, educational level and type of treatment received, half of the women who 
had good sexual function (n=8) were younger than 40 as 50% (n=4) were between the age 
group of 30 to 39. In addition, 50% (n=4) had sexual education before treatment while an 
equal number did not, a greater percentage (62.5%; n=5), had an educational level of grade 
11 to 12 and almost all of them were treated with external beam radiation and brachytherapy 
without concurrent chemotherapy (87.5%; n=7).   
 
 DISCUSSION  4.6
The study provided evidence that the majority of the women (80.3%) were sexually active 
during the four weeks prior to the collection of the data. This high percentage is supported by 
a study conducted by Tangjitgamol et al. (2007) among Thai women in which  93.4% (n=105) 
resumed sexual activity  after treatment. In contrast, some studies report lower numbers. For 
instance, Greimel et al. (2009) in a study conducted in Austria, reported that 56.7% of the 
women resumed sexual activity after they completed treatment for cervical cancer, whilst 
Corrêa et al. (2015), in a study conducted in Brazil, found 40.5% of cervical cancer survivors 
resumed sexual activities.   
Additionally, Jensen et al. (2003), in a study conducted in Denmark, reported that, despite 
changes in the vagina after radiotherapy, 63% of women who were sexually active prior to 
the commencement of treatment continued sexual activity after treatment. Whether the same 
trend would apply to the current study is unknown as sexual activity prior to treatment was 
not explored. However, Jensen et al. (2003) found as time progressed, the proportion of 
those who were not sexually active declined by 25% after three months to 11% after 24 
months (Grimm et al., 2015). The same trend was not observed in the current study as there 
was a slight increase in sexual activity from month three to month six and a slight decline at 
twelve months. It might have been possible that more women in the 12 months group were 
not sexually active before the commencement of treatment compared to the other groups. 
However, a longitudinal study should be completed before definite conclusions can be made.   
Findings from this study further provided evidence that pain experienced during sexual 
activity after treatment persisted in most of the women (81%) even as time progressed, with 
the level of pain highest three months after treatment with little improvement as the time 
progressed (Table 4.4, Fig 4.6). This finding is supported by Jensen et al. (2003), who found 
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that pain persisted in 55% of women for up to two years after treatment. Similarly, Song et al. 
(2012), in a study conducted in Korea, reported a high prevalence of pain persisting over 
time which, according to Bergmark et al. (1999), could be superficial and deep pain. In 
addition, Tangjitgamol et al. (2007) reported that pain increased in 37% of women after 
treatment.  
Bergmark et al. (1999) and Song et al. (2012) ascribe the persistence of pain to the changes 
in the vagina resulting from reduced elasticity of its walls, vaginal bleeding, shortened length 
and reduction in lubrication. Ljuca and Marošević (2011), in a study conducted in Bosnia, 
found more than 95% of women no longer experienced pain and irritation in the vagina 
twelve months after chemo-radiotherapy. However, despite the cessation of these problems, 
the sexual function of the women in their study did not improve due to reasons such as fear 
of cancer reoccurring after intercourse and partners fear of “secondary radiations.”  
Findings that the most affected domains were arousal and desire, while satisfaction was the 
least affected domain in sexual function, are not unique (Table 4.4, Fig 4.6). Reis et al. 
(2010) and  Corrêa et al. (2015) also reported lowest mean score in the desire domain. In 
addition, Rodrigues et al. (2012), in a study conducted in Portugal involving women treated 
with radiotherapy to the pelvis, also recorded the lowest scores in the arousal domain and 
the highest score in the satisfaction domain had the highest mean score.  Bergmark et al. 
(1999) reported that sexual interest was reduced in women who had cervical cancer 
compared to a randomly selected matching sample of healthy women due to the 
insufficiency of sexual hormones caused by the treatment, trauma to the vagina caused by 
radiotherapy and the emotional distress resulting in melancholy which leads to a diminution 
in sexual excitement.  Although sexual desire was one of the most affected domains in the 
current study, which included women up to 12 months after treatment,  (Jensen et al., 2003) 
also found low or no sexual interest in women within a two year period after radiotherapy for 
cervical cancer, which Vaz et al. (2011) attributes to the dyspareunia women experience.  
When considering the domain satisfaction (mean 3.1 in the current study; Table 4.2, Fig 4.2), 
it was found other studies also reported the same trend. Findings by Corrêa et al. (2015) 
showed the highest mean score in this domain (4.34), while Pilger et al. (2012) reported a 
score of 3.71. Corrêa et al. (2015) substantiate these findings by stating women have a 
tendency to adapt to sexual relations as they wish to please their partners even if they have 
little or no desire, while Rodrigues et al. (2012) further illustrated that women adjust to 
having sexual intercourse so as to satisfy partners.  
Furthermore, this study provided evidence that age, education and pre-treatment counselling 
did not have any influence on sexual function. This is in sharp contrast to findings of various 
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studies. For instance, Rodrigues et al. (2012) reported  that sexual dysfunction was more 
prominent in older women, whilst Tsai et al. (2011), in a study conducted in Taiwan, found an 
increase of 16% in the risk of sexual dysfunction with each year rise in age. Supporting this 
finding,  Bae and Park (2015), in a study conducted in Korea, reported that younger age and 
higher levels of education are related to higher sexual function. The discrepancy between 
the findings of the current study and the other studies could possibly be the result of the 
proportion of women older than 50 included in the studies. The current study had a sample 
proportion of 28.5% of women above 50 years of age, whilst this age bracket (>50) 
represented a sample proportion of 46.7% in the study of Bae and Park (2015) and 
approximately 70% in the study of Rodrigues et al. (2012).  Furthermore, Tangjitgamol et al. 
(2007) state the sexual  needs of younger women are higher and with increasing age in 
women, they are more susceptible to sexual issues which are age related. Therefore it was 
interesting to find that the majority of the few women in this study who had a good sexual 
function were younger, between the ages of 30 and 39.  
With regards to educational level, both Corrêa et al. (2015) and Tsai et al. (2011) reported 
that a higher educational level had a positive influence on sexual function. Possible reasons 
are educated women might have access to resources, information and an expansive range 
of knowledge in dealing with the disease. This could assist them in their recovery process, 
coping strategies and adaptation to the changes caused by their cancer and its treatment 
resulting in improved sexual relationships and function.  The current study determined four 
levels of education with most of the women (53.8%) with an educational level ≤ grade 10, 
whilst two levels of education (high and low) were used in the previously mentioned studies 
which could also relate to the differences in the findings. 
Considering the findings of the studies conducted by Lindau et al. (2011) and Tsai et al. 
(2011) it was interesting to note that pre-treatment counselling did not have any influence on 
sexual function in women in the current study. Lindau et al. (2011) and Tsai et al. (2011) 
indicated that lack of sexual education and counselling are risk factors for sexual 
dysfunction, whilst Corrêa et al. (2015) reported that psychotherapy and psycho social 
counselling and discussions on sexual concerns help improve sexual function.  
Finally, the study provided evidence that the majority of the women (94.6%) experienced 
sexual dysfunction which persisted over time (Table 4.4, Fig 4.6).  This percentage is higher 
than the 86.5% reported by Liu et al. (2015) and the 80% reported by Corrêa et al. (2015). 
Jensen et al. (2003) found a similar trend over a two year period and reported that sexual 
dysfunction was persistent throughout the period.  According to Bergmark et al. (1999) and 
Jensen et al. (2003), ovarian failure caused by chemotherapy and radiotherapy, fatigue, 
vaginal changes, as well as emotional distress and fear of a recurrence of the cancer may 
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be associated to the high prevalence of sexual dysfunction which remains persistent long 
after treatment.  
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CHAPTER 5 
JUSTIFICATION, LIMITATIONS AND RECOMMENDATIONS 
 
 INTRODUCTION 5.1
In Chapter 4, the findings of the study were presented and discussed in detail. This chapter 
focuses on the justification, limitations and recommendations. The study will also be 
concluded. 
 
 JUSTIFICATION OF THE STUDY 5.2
The study will be justified in terms of its purpose and aims. The purpose of the study was to 
explore the sexual functioning of women after being treated for cervical cancer at an 
academic hospital in Johannesburg, South Africa. The study aimed at exploring the sexual 
functioning of women treated for cervical cancer in the third, sixth and twelfth months after 
completing the treatment. 
Chapter 3 described the research design and methods in detail. Chapter 4 presented the 
findings and an in depth discussion of the findings. The sexual function of women at three, 
six and twelve months after treatment were presented in terms of the domains of sexual 
function, sexual dysfunction and good sexual function. Comparisons were also made. It can 
therefore be stated that this study is justified as the purpose and aims were met.  
 
 LIMITATIONS OF STUDY 5.3
Using a cross sectional design disallowed investigating changes in the same respondents 
over time. A longitudinal design could result in more accurate findings regarding the sexual 
function of women over time. Additionally, the presence of sexual dysfunction in partners 
was not investigated or ruled out which could also have influenced the findings. 
Sample size outcome variable from a previous validation study by Meston (2003) was used 
in the calculation of the sample size in this study as opposed to a more recent validation 
study by Baser et al (2012). The study by Meston (2003) was used because its study 
population were women who already had identified sexual dysfunctions while the latter study 
was in female cancer survivors without established sexual dysfunction. 
Although some women indicated being single, this did not rule out the presence of a sexual 
partner. This is due to the fact that marital status does not rule out the presence or absence 
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of sexual partners. Also, sexually inactive women were not excluded in the study and they 
only gave specific scores in the domain of satisfaction while their sexual function was 
calculated based on the minimum scores for each domain. Reasons for their sexual inactivity 
were not explored as it was out of the scope of this study.  
 
 RECOMMENDATIONS FOR CLINICAL PRACTICE 5.4
Although sexual function after treatment was not influenced by sexual counselling before 
treatment, nurses practicing in cancer care settings should not become discouraged and 
discontinue this standard practice. It might be helpful to assess the patient‟s needs regarding 
sexual issues prior to treatment, at regular intervals after treatment and focus on these 
needs during the counselling sessions. Different models of sexual care can also be 
considered. In addition, a longitudinal study could be conducted which would allow 
assessing sexual function over time and guide nursing interventions to improve sexual 
function of women.  
 
 CONCLUSION  5.5
The study provided evidence that the majority of women treated for cervical cancer at an 
academic hospital in the Gauteng Province live with long lasting sexual dysfunction affecting 
all the domains of their sexual functioning. Although sexual dysfunction reached the highest 
level in the third month after treatment, there was little improvement over time. Age, 
educational level and sexual counselling before treatment did not influence sexual function.  
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APPENDIX A: INFORMATION LETTER 
STUDY TITLE: Sexual function in women after cervical cancer treatment at an academic 
hospital in Johannesburg, South Africa. 
INSTITUTION: Department of Nursing Education, Faculty of Health Sciences, University of 
the Witwatersrand. 
Good day Madam, 
My name is Imoleayo Fakunle, a Masters student at the Department of Nursing Education, 
University of Witwatersrand. I would like to invite you to participate in a study I am currently 
conducting the title is “Sexual function in women after cervical cancer treatment.”  You 
can choose whether to participate in the study and if you agree, you will not lose your place 
in the queue. Should you agree to participate, I will ask you some questions and write your 
answers on a sheet of paper, which will be numbered without your name on it. This will take 
about 20 minutes of your time. You will give me permission to do this by signing a consent 
form. Should you experience sadness while answering these questions, I will ask Sister 
Makama, who is in charge of the unit, to counsel you if you so wish.  
This study will not benefit you directly as a participant, but the findings may assist nurses 
understand, assess and provide care which may help improve sexual function in women 
during and after cervical cancer treatment. If you decide not to participate in this study, there 
will be no adverse effects as you will still receive your required care. Even if you choose to 
withdraw from the study, you will not lose any entitled care and benefits. Your name will not 
appear on the sheet of paper which has the answers to your questions and once I place this 
in the envelope, I will not be able to identify which belongs to you. 
All information you give will be confidential. The findings and records of the study may be 
looked at by the Research Ethics Committee for quality and to inspect how I have analysed 
what you have told me. After I have analysed the information, all data will be sealed in an 
envelope and kept safe in the Department of Nursing Education for a period of two years. 
Once the findings have been published in a research report, the data will be destroyed. Your 
identity will not be revealed in this report. 
If you have any questions or need further information, please feel free to contact me on 
bami246@yahoo.com or 0780052786. If you have any question about your rights as a study 
participant or any concerns about any aspect of the study, please call Prof Peter Cleaton-
Jones at the Ethics Department of the University of the Witwatersrand on +27 11 717 1234. 
 
Thank you. 
 
 
Yours faithfully, 
Imoleayo Fakunle 
Department of Nursing Education 
University of Witwatersrand 
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APPENDIX B: INFORMED CONSENT 
 
Sexual function in women after cervical cancer treatment at an Academic Hospital in 
Johannesburg, South Africa 
 
I confirm that I have been informed by the researcher about the nature, conduct and benefits 
of the study. Also, I have read and understood the content of the participant information 
sheet and informed consent on the study.  
 
I am fully aware that my personal information will be processed anonymously in the reports 
of the study. I understand I have the right to withdraw my participation in the study. I have 
asked questions and made all necessary clarifications. I am prepared to participate in the 
study.  
 
 
 
 
 
Participant‟s signature      Date and time 
  
 
 
I, Imoleayo Fakunle confirm that the above participant has been informed about the nature 
and conduct of the above study. 
 
 
 
Researcher‟s signature      Date and time 
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APPENDIX C: REQUEST FOR PERMISSION 
Department of Nursing 
Education, 
Faculty of Health Sciences, 
University of Witwatersrand, 
7, York Road, Parktown, 2193 
Johannesburg 
Date …………… 
The Chief Executive Officer, the Nursing Manager and the Unit Manager, 
Charlotte Maxeke Johannesburg Academic Hospital, 
Parktown, Johannesburg. 
Dear Sir/Madam 
REQUEST FOR PERMISSION TO CONDUCT A RESEARCH STUDY IN THE HOSPITAL 
My name is Fakunle Imoleayo and I am a postgraduate student at the Department of 
Nursing Education, University of Witwatersrand and hereby request permission to conduct a 
research in the hospital titled „Sexual function in women after cervical cancer treatment.’ 
Cervical cancer is rated as the fourth highest cancer in women in the world and the fourth 
most common cause of death in women worldwide, with the highest being lung cancer. 
Guidelines on the management of cervical cancer ensure effective evidence based health 
outcome for women through the selection of appropriate treatment regimen depending on 
the stage of the disease. These treatment modalities have significant effects and 
complications on the sexual function of women. This study could provide baseline data and 
add to the knowledge in the field of Nursing Science. The study may also create awareness 
amongst nurses and help them provide comprehensive and evidence based care for the 
sexual functioning in women during cervical cancer treatment. 
On approval by the Post Graduate Research Committee of the Faculty of Health Sciences, 
clearance from the Ethics Committee of Research and Human subjects of the University of 
Witwatersrand, I intend to commence the research project to explore the sexual function of 
women on cervical cancer treatment in the radiation oncology department of the hospital. 
I wish to assure you that informed consent will be obtained from the participants and 
confidentiality will be ensured. A copy of the report will be made available to you on 
completion of the study if requested. 
Yours faithfully, 
Fakunle Imoleayo 
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APPENDIX D: DATA COLLECTION INSTRUMENT  
SEXUAL FUNCTION IN WOMEN AFTER CERVICAL CANCER TREATMENT 
Section A 
General information: 
1. Age__________________________________ 
2. Educational level ________________________ 
3. Employment status _______________________ 
4. Marital status:        Single                   Married                     Divorced 
5. Did you have sexual counselling before treatment?  Yes         No 
6. Which treatment did you receive?  
External beam radiation   brachytherapy  chemotherapy  
7. Period of follow up appointment    3 months   6 months    12 months  
SECTION B: FEMALE SEXUAL FUNCTION INDEX (FSFI) 
INSTRUCTIONS: These questions ask about your sexual feelings and responses during the 
past four weeks. Please answer the following questions as honestly and clearly as possible. 
Your responses will be kept completely confidential. In answering these questions, the 
following definitions apply: 
Sexual activity can include caressing, foreplay, masturbation and vaginal intercourse.  
Sexual intercourse is defined as penile penetration (entry) of the vagina. 
Sexual stimulation includes situations like foreplay with a partner, self-stimulation 
(masturbation), or sexual fantasy. 
Check ONLY one box per question 
Sexual desire or interest is a feeling that includes wanting to have a sexual experience, 
feeling receptive to a partners sexual initiation and thinking or fantasising about having sex. 
1. Over the past 4 weeks, how often did you feel sexual desire or interest? 
Almost always or always       
Most times (more than half the time)   
Sometimes (about half the time)   
A few times (less than half the time)   
Almost never or never    
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2. Over the past 4 weeks. How would you rate your level (degree) of sexual desire or 
interest? 
Very high      
High       
Moderate 
Low 
Very low or none at all 
 
 
Sexual arousal is a feeling that includes both physical and mental aspects of sexual 
excitement. It may include feelings of warmth or tingling in the genitals, lubrication, 
(wetness), or muscle contractions. 
3. Over the past 4 weeks, how often did you feel sexually aroused (“turned on”) during 
sexual activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
4. Over the past 4 weeks how would you rate your level of sexual arousal (turn on) 
during sexual activity or intercourse? 
No sexual activity 
Very high 
High  
Moderate  
Low  
Very low or none at all 
 
5. Over the past 4 weeks, how confident were you about becoming sexually aroused 
during sexual activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
6. Over the past 4 weeks, how often have you been satisfied with your arousal 
(excitement) during sexual activity or intercourse? 
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No sexual activity 
Almost always or always    
Most times (more than half the time) 
Sometimes (about half the time) 
A few times(less than half the time)     
Almost never or never 
 
7. Over the past 4 weeks, how often did you become lubricated (“wet”) during sexual 
activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
 
8. Over the past 4 weeks, how difficult was it to be lubricated (“wet”) during sexual 
activity or intercourse? 
No sexual activity 
Extremely difficult or impossible 
Very difficult 
Difficult 
Slightly difficult 
Not difficult 
 
9. Over the past 4 weeks, how often did you maintain your lubrication (“wetness”) until 
completion of sexual activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
10. Over the past 4 weeks, how difficult was it to maintain your lubrication (“wetness”) 
during sexual activity or intercourse? 
No sexual activity 
Extremely difficult or impossible 
Very difficult 
Difficult 
Slightly difficult 
Not difficult 
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11. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often 
did you reach orgasm (climax)? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
12. Over the past 4 weeks, when you had sexual stimulation or intercourse, how 
difficult, was it for you to reach orgasm (climax)? 
 No sexual activity 
Extremely difficult or impossible 
Very difficult 
Difficult 
Slightly difficult 
Not difficult 
 
13. Over the past 4 weeks, how satisfied were you with your ability to reach orgasm 
(climax) during sexual activity or intercourse? 
No sexual activity 
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
 
14. Over the past 4 weeks, how satisfied have you been with the amount of emotional 
closeness during sexual activity between you and your partner?  
No sexual activity 
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
 
15. Over the past 4 weeks, how satisfied have you been with your sexual relationship 
with your partner?  
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
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16. Over the past 4 weeks, how satisfied have you been with your overall sexual life?  
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
 
17. Over the past 4 weeks, how often did you experience discomfort or pain during 
vaginal penetration? 
Did not attempt intercourse 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
18. Over the past 4 weeks, how often did you experience discomfort or pain following 
vaginal penetration? 
Did not attempt intercourse 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
 
19. Over the past 4 weeks, how would you rate your level (degree) of discomfort or pain 
during or following vaginal penetration? 
Did not attempt intercourse 
Very high 
High 
Moderate 
Low 
Very low or none at all 
 
 
Thank you for completing this questionnaire 


